PegBio Pharma's stock soared 15.53% during intraday trading on Thursday, marking a significant recovery in its share price.

The sharp rise represents a technical rebound following a steep selloff in the previous session, which was triggered by the full expiration of the company's IPO lock-up period. As PegBio Pharma marked its one-year listing anniversary, all pre-IPO shareholders' restricted shares became eligible for sale simultaneously, creating intense selling pressure that drove the stock down substantially. With the bulk of this lock-up expiry selling pressure largely absorbed, bargain hunters stepped in to drive the recovery.

PegBio Pharma is a biotechnology company focused on chronic metabolic diseases, with its core product being a near-commercialization long-acting GLP-1 receptor agonist primarily targeting Type 2 diabetes and obesity.